Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung cancer
Phase 2
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000004573
- Lead Sponsor
- First Department of Internal Medicine, Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
1) Previously treated with paclitaxel and / or bevacizumab 2) Patients with brain metastasis 3) Patients with hemoptysis 4) Patients receiving therapeutic anticoagulation 5) Patients with complications like below Active infection Acute myocardial infarction during recent 6 months or the other severe heart disease Uncontrollable diabetes mellitus Uncontrollable hypertension Active psychological disease 6) Hypersensitivity to paclitaxel and / or bevacizumab 7) Active concomitant malignancy 8) Pregnancy or lactation 9) Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Three-months progression free rate
- Secondary Outcome Measures
Name Time Method Overall response rate Overall survival Toxicity